Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 15, 2002BloodOpen Access

Rituximab treatment results in impaired secondary humoral immune responsiveness

View Full Paper
Ask AI
Bookmark
Share

Authors

LKLizet E. van der KolkThe Netherlands Cancer InstituteJBJoke W. BaarsThe Netherlands Cancer InstituteMPMartin H. PrinsVascular Medicine

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Kolk et al. (2002) studied this question.

synapsesocial.com/papers/6a0ecc03218372ada647bc58https://doi.org/10.1182/blood.v100.6.2257
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.1998 · 2,771 citations
  2. 2Tumor-Specific Idiotype Vaccines in the Treatment of Patients With B-Cell Lymphoma — Long-Term Results of a Clinical Trial1997 · 457 citations
  3. 3Standardization of Poliovirus Neutralizing Antibody Tests1984 · 91 citations
  4. 4Immune function of successfully treated lymphoma patients.1976 · 41 citations